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Abstract
OBJECTIVE—To evaluate the trends in survival for infants with critical congenital heart defects 
(CCHDs) and to examine the potential impact of timing of diagnosis and other prognostic factors 
on survival.
METHODS—We performed a retrospective population-based cohort study in infants born with 
structural congenital heart defects (CHDs) between 1979 and 2005 and ascertained by the 
Metropolitan Atlanta Congenital Defects Program. We estimated Kaplan-Meier survival 
probabilities for 12 CCHD phenotypes by birth era and timing of diagnosis among infants without 
noncardiac defects or chromosomal disorders and used stratified Cox proportional hazards models 
to assess potential prognostic factors.
RESULTS—Of 1 056 541 births, there were 6965 infants with CHDs (1830 with CCHDs). One-
year survival was 75.2% for those with CCHDs (n = 1336) vs 97.1% for those with noncritical 
CHDs (n = 3530; P < .001). One-year survival for infants with CCHDs improved from 67.4% for 
the 1979–1993 birth era to 82.5% for the 1994–2005 era (P < .001). One-year survival was 71.7% 
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for infants with CCHDs diagnosed at ≤1 day of age (n = 890) vs 82.5% for those with CCHDs 
diagnosed at >1 day of age (n = 405; P < .001). There was a significantly higher risk of 1-year 
mortality for infants with an earlier birth era, earlier diagnosis, and low birth weight and whose 
mothers were <30 years old.
CONCLUSIONS—One-year survival for infants with CCHDs has been improving over time, yet 
mortality remains high. Later diagnosis is associated with improved 1-year survival. These 
benchmark data and identified prognostic factors may aid future evaluations of the impact of pulse 
oximetry screening on survival from CCHDs.
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Congenital heart defects (CHDs) occur in ~1 in every 110 births in the United States,1 with 
~25% of cases comprising a group known as critical congenital heart defects (CCHDs).2 If 
not detected promptly, CCHDs may have catastrophic consequences.3,4 This delayed 
diagnosis has been shown to lead to significant mortality as well as substantial short- and 
long-term morbidity for survivors.5,6
Pulse oximetry is a simple, noninvasive bedside test that can accurately detect the 
percentage of hemoglobin saturated with oxygen; infants with CCHDs typically have a low 
percentage of saturation even before the onset of symptoms.7 In a recent review of 13 
studies using pulse oximetry to screen for CCHDs, pulse oximetry screening (POS) was 
shown to have a sensitivity of 76.5% and a specificity of 99.9%.8 When screening is 
performed after 24 hours of age, there is an estimated very low false-positive rate of 0.05%. 
As such, POS is already in use in many parts of Europe7,9–11 and has recently been added to 
the Recommend Uniform Screening Panel for newborns in the United States.12,13
However, the impact that POS will have on outcomes for infants with CCHDs is unclear.14 
To understand this potential impact in the United States, we used population-based data on 
survival for children with CCHDs to evaluate the trends in survival for infants with CCHDs 
and to examine the potential impact of timing of diagnosis and other prognostic factors on 
survival.
METHODS
Data Sources
Children with CHDs were ascertained by the Metropolitan Atlanta Congenital Defects 
Program (MACDP), an active, population-based surveillance system that has been 
previously well described. 15 Briefly, the MACDP was begun in 1967 to monitor the 
prevalence of congenital defects in metropolitan Atlanta, Georgia. The MACDP operates in 
collaboration with and on behalf of the Georgia Division of Public Health by the Georgia 
Department of Human Resources and has approval of the institutional review board of the 
Centers for Disease Control and Prevention. The monitoring program includes those 
children in whom a major birth defect is diagnosed before 6 years of age and whose mothers 
had a primary residence in the metropolitan Atlanta 5-county area at the time of delivery. 
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The MACDP actively collects clinical and demographic information on all identified cases 
through review of medical records and autopsy reports. Survival status is determined via 3 
possible methods: (1) review of available clinical records, (2) linkage with vital records 
from the state of Georgia, and (3) linkage with the National Death Index. For this project, 
National Death Index records were available from January 1, 1979, to December 31, 2006. 
With 1-year survival as the primary endpoint, the birth cohort was thus limited to those born 
from January 1, 1979, to December 31, 2005.
All cases in the MACDP with International Classification of Disease, Ninth Revision, 
modified British Pediatric Association codes for CHDs are reviewed and classified by 
experts in pediatric cardiology by using a standard clinical nomenclature adopted from the 
Society of Thoracic Surgeons and a schema based on current understanding of development 
morphogenesis. 16 All infants identified with a CHD in the MACDP were included in the 
baseline characteristics summary and the prevalence estimates, but those with either a 
chromosomal disorder or a noncardiac defect were excluded from the survival and 
proportional hazards analyses. For this project, the term CCHDs includes 12 CHDs that are 
likely to be detected by POS some or most of the time, including 7 primary and 5 secondary 
screening targets.6 Primary targets for screening are as follows: hypoplastic left heart 
syndrome, pulmonary atresia, tetralogy of Fallot, transposition of the great arteries, tricuspid 
atresia, truncus arteriosus, and total anomalous pulmonary venous return.6,13 Secondary 
targets are coarctation of the aorta, double outlet right ventricle, Ebstein’s anomaly, 
interrupted aortic arch, and single ventricle.6 Although severe cases of pulmonary stenosis 
and aortic stenosis are often considered critical,6 these defects were not considered as 
CCHDs for this analysis because disease severity is not routinely collected or classified by 
the MACDP.
Outcomes and Prognostic Factors
Among infants with isolated CHDs (those without chromosomal abnormalities or 
noncardiac defects), we first analyzed survival for infants with CCHDs versus those with 
noncritical CHDs. Within the CCHD cohort, we then assessed the following: (1) the 
difference in 1-year survival for primary versus secondary screening targets, (2) the trend in 
1-year survival from 1979 to 2005 for all cases, and (3) the difference in 1-year survival 
based on timing of diagnosis (diagnosed at >1 day of age versus diagnosed at ≤1 day of age, 
including prenatal diagnoses). The 1-day of age cutoff for timing of diagnosis was chosen 
because this period most closely reflects the timing of potential diagnoses via the proposed 
POS algorithm in the United States.13 We did not assess diagnosis before versus after 
discharge from the newborn nursery, because the MACDP ascertains only day of diagnosis, 
not inpatient status at time of diagnosis.
As possible prognostic factors for mortality, we considered the following variables for 
which there was information available: birth era (1979–1993 vs 1994–2005), age at 
diagnosis (diagnosed at >1 day of age versus diagnosed at ≤1 day of age), race (white versus 
nonwhite), birth weight (<2500 vs ≥2500 g), gender, maternal age (<30 vs ≥30 years), and 
neighborhood poverty status (<20% in census tract living in poverty vs ≥20%).
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Statistical Analyses
We used χ2 analyses to compare baseline characteristics between the CCHD cohort and the 
noncritical CHD cohort. Prevalence estimates were determined by using Poisson 
distribution. To compare survival, we estimated Kaplan-Meier survival probabilities and 
used the log-rank test to determine significance (P < .05). To evaluate potential risk factors 
for mortality among those with CCHDs, we first constructed univariate Cox proportional 
hazards models to determine the significance of the hazard ratio (HR) for each risk factor by 
using the Wald test. Those risk factors with a P < .20 were then included in a multivariate, 
stratified Cox proportional hazards model with the use of backward elimination to determine 
those factors meeting significance at the P = .05 level after adjustment. Because 
neighborhood poverty status did not satisfy the proportional hazards assumption, the final 
multivariate model was stratified on this variable to account for potential confounding. All 
analyses were performed with the use of SAS, version 9.3 (SAS Institute, Cary, NC).
RESULTS
Of the 1 056 541 live births in the 5-county metropolitan Atlanta region from 1979 to 2005, 
there were 6965 children identified with a CHD by the MACDP. Of these, 1830 (26.3%) 
had a CCHD, with 1204 (17.3%) having 1 of the 7 primary targets of CCHD screening and 
626 (9.0%) having 1 of the 5 secondary targets. The overall estimated live birth prevalence 
was 65.9 per 10 000 live births for all CHDs, 17.3 per 10 000 live births for CCHDs, and 
11.4 per 10 000 live births for the primary targets of CCHD screening. Compared with those 
with noncritical CHDs, those in the CCHD cohort were more likely to be male, to have 
noncardiac defects, and to be born to a mother under the age of 30 years, but they were less 
likely to be of low birth weight. There were no significant differences with respect to race, 
neighborhood poverty status, or presence of chromosomal syndromes. Among those without 
chromosomal or noncardiac defects, those with CCHDs were more likely to be diagnosed on 
or before 1 day of age than those with noncritical CHDs (Table 1). There was an increase in 
the detection of all CHDs from 1979 to 2005, increasing from 50.1 cases per 10 000 live 
births in 1979–1986 to 84.5 cases per 10 000 live births in 2000–2005 (Table 2).
One-year survival was significantly greater for those with isolated noncritical CHDs 
(97.1%) compared with those with isolated CCHDs (75.2%; P < .001). Similarly, survival to 
adulthood (18 years of age) was significantly greater for those with isolated noncritical 
CHDs (95.4%) than for those with isolated CCHDs (68.8%; P < .001) (Fig 1). Among those 
with CCHDs, those with 1 of the 5 secondary targets of CCHD screening had better 1-year 
survival (85.1%) than those with 1 of the 7 primary targets of CCHD screening (70.2%; P <. 
001). One-year survival for infants with CCHDs significantly improved over time, from 
67.4% for the 1979–1993 birth era to 82.5% for the 1994–2005 era (P < .001). Those 
diagnosed with CCHDs on or before 1 day of age had poorer 1-year survival (71.7%) 
compared with those with CCHDs diagnosed after 1 day of age (82.5%; P < .001) (Fig 2).
In the univariate analysis, risk factors associated with mortality at the P < .20 level included 
birth era, timing of diagnosis, gender, maternal age, and low birth weight. After including 
these variables in a multivariate model and performing backward elimination, factors with a 
significantly increased proportional hazards of mortality were earlier birth era (HR = 2.65; 
Oster et al. Page 4
Pediatrics. Author manuscript; available in PMC 2015 June 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
95% confidence interval [CI]: 2.11–3.32) and low birth weight (HR = 1.73; 95% CI: 1.34–
2.24); those factors with a significantly decreased hazards were diagnosis at >1 day of age 
(HR = 0.54; 95% CI: 0.42–0.69) and maternal age ≥30 years (HR = 0.77; 95% CI: 0.62–
0.97) (Table 3).
DISCUSSION
As anticipated, our findings reveal that infants with CCHDs have poorer survival than those 
with noncritical CHDs, but that survival for the critical subset has been improving over time. 
Still, with only 82.5% 1-year survival in the most recent birth era, CCHDs remain a priority 
for public health action. Implementing POS is one such public health effort to improve 
survival. In our cohort, those with a later diagnosis had better survival than those with an 
earlier diagnosis. Importantly, there were several other significant prognostic factors that 
affected survival even after accounting for differences in timing of diagnosis, including birth 
era, maternal age, and birth weight. Future evaluations of the impact of POS should include 
these factors when assessing survival.
With regard to the temporal trends of birth prevalence of CHDs, there was an increase in the 
detection of all CHDs from 1979 to 2005, increasing from 50.1 cases per 10 000 live births 
in 1979–1986 to 84.5 cases per 10 000 live births in 2000–2005. This increase was primarily 
driven by the cases of noncritical CHDs, a phenomenon likely explained by increased 
ascertainment of those defects.2,17 The live birth prevalence of CCHDs (~17 per 10 000 live 
births) remained stable throughout the time course. These findings are similar to prevalence 
estimates from a recent evaluation of CHDs in Europe.18
Our findings with regard to the occurrence and outcomes of delayed diagnosis of CCHDs 
are similar to those of smaller European studies. In our study, 31.3% of isolated CCHD 
cases were diagnosed beyond the first day of life, a proportion comparable to the ~25% of 
cases diagnosed after discharge from the hospital in other studies.19–21 Similarly, our study 
is in agreement with smaller studies in the finding that infants with a later diagnosis of a 
CCHD had improved survival compared with those with a CCHD diagnosed earlier. In a 
review of 286 neonates (<1 month of age) undergoing cardiac surgery for CHDs in the 
United Kingdom in 1999–2002, infants with CHDs diagnosed after discharge from the 
hospital after birth had improved postoperative survival (survival to discharge from the 
hospital) compared with those with CHDs diagnosed prenatally; however, there was no 
difference in survival compared with those with CHDs diagnosed postnatally before 
discharge from the maternity unit.19 In a study in 259 infants with CCHDs in Sweden who 
underwent surgery before 2 months of age in 1993–2001, infants with CCHDs diagnosed 
after discharge from the maternity unit had better early postoperative survival (survival of 
>30 days after surgery) than those with CCHDs diagnosed before discharge.20 The precise 
explanation as to why those whose CCHDs are diagnosed earlier seem to have poorer 
survival is unclear. We believe that this observation is likely a reflection of the severity of 
disease, ie, those that have more severe disease are more likely to be diagnosed earlier and 
are also more likely to have poorer survival. Future studies are warranted to evaluate this 
hypothesis.
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Of the other factors that we analyzed, our findings for low birth weight22 and earlier birth 
era23 are consistent with the findings of previous studies. Interestingly, although female 
infants24,25 and nonwhites26 have been shown to have increased in-hospital mortality after 
congenital heart surgery in previous studies, neither gender nor race was revealed to be a 
significant risk factor for 1-year survival in our CCHD cohort. Conversely, whereas 
maternal age was not shown to be associated with survival in a recent study in children with 
functional single ventricle defects, older maternal age was found to be a protective factor in 
our analysis.27
An important measure of the success of any screening program is its ability to improve 
outcomes for those being screened.28 As such, our findings underscore the notion that the 
goal of POS should not be to attain outcomes for those cases diagnosed through screening 
similar to the outcomes of those cases diagnosed earlier by other means (prenatal ultrasound, 
symptoms prompting evaluation). Rather, the goal should be to improve the survival for 
those cases currently experiencing delayed diagnosis, which might be a group with lower 
severity of disease. In our analysis, there were an estimated 17.3 cases of CCHDs per 10 000 
live births, with 31.3% of cases (5.4 cases per 10 000 births) being diagnosed after 1 day of 
age. With a 1-year survival rate of 82.5%, there would be an expected 0.94 infant deaths per 
10 000 live births for children with a late-diagnosed CCHD. In the United States, with 4 131 
019 births in 2009,29 this would translate into ~390 deaths annually in infants with a CCHD 
diagnosed after 1 day of age.
It is unclear what proportion of deaths in children with CCHDs is directly attributable to a 
delayed diagnosis of a CCHD and thus would be potentially preventable with POS. Existing 
studies aimed at addressing this question have primarily focused on diagnoses made either 
postmortem or at the time of acute decompensation leading to death (not just delayed 
diagnoses), relied on multiple assumptions, and were limited by their amount of clinical 
data. Yet, they do help inform expectations of the impact of POS. In California it was 
estimated that there were 1.7 cases of missed CCHD diagnoses contributing to death per 100 
000 live births from 1989 to 2004, although this number was markedly decreasing over 
time.30 In a previous analysis of MACDP data from 1990 to 2001, it was estimated that 
infant mortality from undetected CCHDs was 1.2 deaths per 100 000 live births.31 These 
estimates suggest that ~50 to 70 deaths annually in the United States might be due to missed 
diagnosis. Estimates as to the impact of delayed or missed CCHD diagnosis worldwide are 
not known.
This study has several strengths. First, a major strength of our study is the robust, active case 
ascertainment system of the MACDP. Instead of relying on passive reports of CHDs, 
abstractors regularly review birth records, prenatal records, pediatric records, genetic 
records, cardiology records at selected offices, laboratory reports, and autopsy reports in an 
effort to attain accurate reports of new diagnoses of birth defects. Second, the identified 
cases of cardiac birth defects undergo rigorous review by a team of pediatric cardiologists 
and are classified according to a state of the science classification and coding system, thus 
optimizing the accuracy of the data for surveillance and research.32 Finally, the data have 
been actively collected over 25 years on a population level, allowing us to monitor important 
public health trends as surgical and medical care of children with CHDs has advanced.
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However, this study is not without its limitations. Whereas there are strong data on 
diagnosis, there are limited data on subsequent hospital course and surgical interventions, 
thus limiting our analyses. We were not able to control for severity of disease, a factor that 
we hypothesize contributes to both earlier diagnosis and poorer survival. In addition, as 
noted in the Methods section, without information on severity of disease and clinical course, 
we could not include cases of critical aortic stenosis or critical pulmonary stenosis in our 
CCHD case definition. Similarly, without adequate surgical data, we cannot determine 
which deaths may have been due to palliative care options nor can we assess trends in 
surgical mortality.
CONCLUSIONS
One-year survival for infants with CCHDs has been improving over time, yet mortality 
remains high. As such, improving survival from CCHDs remains an opportunity for public 
health action. Evaluations of POS or other screening modalities for CCHDs should include 
assessments of improvements in outcomes, particularly long-term survival. Our findings of 
trends in and prognostic factors for survival of children with CCHDs may aid such 
evaluations.
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WHAT’S KNOWN ON THIS SUBJECT
Pulse oximetry testing in newborns can detect asymptomatic cases of critical congenital 
heart defects and has been added to the US Recommended Uniform Screening Panel. 
However, the impact that earlier diagnosis may have on survival in this population is 
unclear.
WHAT THIS STUDY ADDS
One-year survival for infants with critical congenital heart defects has been improving 
over time, yet mortality remains high. Survival has been greatest for those diagnosed 
after 1 day of age and may increase more with screening using pulse oximetry.
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FIGURE 1. 
Survival for persons with CCHDs versus noncritical CHDs: Atlanta, Georgia, 1979–2005. 
These data exclude persons with noncardiac defects and chromosomal syndromes.
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FIGURE 2. 
One-year survival for infants with CCHDs by age at diagnosis: Atlanta, Georgia, 1979–
2005. These data exclude persons with noncardiac defects and chromosomal syndromes.
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TABLE 1
Baseline Characteristics of Infants With CCHDs Versus Noncritical CHDs in Metropolitan Atlanta, Georgia: 
1979–2005
CCHDs Noncritical CHDs P
Gender <.001
  Male 1027 (56.1) 2459 (47.9)
  Female 802 (43.9) 2671 (52.1)
Maternal age .01
  <20 years 196 (10.7) 473 (9.2)
  20–24 years 412 (22.5) 1059 (20.6)
  25–29 years 492 (26.9) 1354 (26.4)
  ≥30 years 729 (39.9) 2249 (43.8)
Birth weight <.001
  <2500 g 415 (22.7) 1368 (26.6)
  ≥2500 g 1415 (77.3) 3767 (73.4)
Race .19
  White
  Nonwhite 897 (49.0) 2609 (50.8)
Neighborhood poverty status .85
  Neighborhood poverty <20% 1495 (84.2) 4172 (84.0)
  Neighborhood poverty ≥20% 280 (15.8) 793 (16.0)
Presence of a chromosomal syndrome
  No 1596 (87.9) 4236 (86.2)
  Yes 220 (12.1) 678 (13.8)
Presence of noncardiac defects (without a syndrome)   
  No 1557 (85.7) 4339 (88.3)
  Yes 259 (14.3) 575 (11.7)
Age at diagnosisa <.001
  ≤ 1 day old 890 (68.7) 1776 (51.6)
  >1 day old 405 (31.3) 1666 (48.4)
Data are n (%). CCHDs include primary targets (hypoplastic left heart syndrome, transposition of the great arteries, tricuspid atresia, truncus 
arteriosus, tetralogy of Fallot, total anomalous pulmonary venous return, and pulmonary atresia) and secondary targets (interrupted aortic arch, 
coarctation of the aorta, double outlet right ventricle, Ebstein’s anomaly, and single ventricle) of screening. Noncritical CHDs include all other 
structural congenital heart defects.
a
Excludes those with noncardiac defects and chromosomal syndromes.
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TABLE 2
Live Birth Prevalence of CHDs and CCHDs in Metropolitan Atlanta, Georgia: 1979–2005
Period Births Cases per 10 000 Live Births (95% CI)
All CHDs All CCHDs CCHD Primary Targets
1979–1986 228 566 50.1 (47.3–53.1) 17.1 (15.5–18.9) 11.9 (10.5–13.4)
1987–1993 264 060 55.0 (52.3–57.9) 16.4 (14.9–18.0) 11.3 (10.1–12.6)
1994–1999 255 847 68.9 (65.8–72.2) 17.9 (16.4–19.7) 11.3 (10.1–12.7)
2000–2005 308 068 84.5 (81.3–87.8) 17.8 (16.4–19.3) 11.2 (10.1–12.5)
Total 1 056 541 65.9 (64.4–67.5) 17.3 (16.5–18.1) 11.4 (10.8–12.1)
CCHDs include primary targets (hypoplastic left heart syndrome, transposition of the great arteries, tricuspid atresia, truncus arteriosus, tetralogy of 
Fallot, total anomalous pulmonary venous return, and pulmonary atresia) and secondary targets (interrupted aortic arch, coarctation of the aorta, 
double outlet right ventricle, Ebstein’s anomaly, and single ventricle) of screening.
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TABLE 3
Stratified Cox Proportional HRs for 1-Year Mortality in Infants Born With CCHDs: Atlana, Georgia, 1979–
2005
Variable Referent Group HRa 95% CI P
Born 1979–1993 Born 1994–2005 2.65 2.11–3.32 <.001
Diagnosed at >1 day old Diagnosed at ≤1 day old 0.54 0.42–0.69 <.001
Maternal age ≥30 years Maternal age <30 years 0.77 0.62–0.97 .02
Birth weight <2500 g Birth weight ≥2500 g 1.73 1.34–2.24 <.001
Infants with noncardiac defects and chromosomal syndromes were excluded.
a
Each HR was adjusted for the other variables in the table. The model was stratified on neighborhood poverty status because it violated the 
proportional hazards assumption.
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